Rockwell Medical shares surge 10.98% premarket after reporting adjusted EBITDA profitability and securing long-term contracts amid cash reserves growth.

Rockwell Medical surged 10.98% in premarket trading following the announcement of its third-quarter 2025 results, which included achieving profitability on an Adjusted EBITDA basis and a $23.7 million cash position. The company reiterated 2025 guidance for net sales of $65–70 million, highlighted new long-term contracts (including a $1 million annual agreement in Florida), and emphasized operational efficiency and customer diversification. Despite a 44% year-over-year sales decline due to a major customer transition, the stock reacted positively to the improved Adjusted EBITDA, strengthened cash reserves, and strategic initiatives, including expansion in home dialysis and bicarbonate cartridge adoption. These factors signaled progress toward sustainable profitability and growth, outweighing near-term sales concerns.